Grant Chamberlain - Immutep Non-Executive Director
| IMMP Stock | USD 2.69 0.02 0.75% |
Director
Mr. Grant Chamberlain is NonExecutive Director of the Company. Mr Chamberlain is a corporate adviser and entrepreneur. He has over 20 years experience in investment banking and has advised on many of the largest mergers and acquisitions transactions in Australia during that time. Mr Chamberlain was Head of Mergers Acquisitions and Financial Sponsors Australia at Bank of America Merrill Lynch until June 2017 and prior to joining Bank of America Merrill Lynch in 2013, Mr Chamberlain held senior positions at Nomura Australia and Deutsche Bank. He began his career as a corporate lawyer at Freehill Hollingdale Page. Mr Chamberlain earned a Bachelor of Laws with Honours and a Bachelor of Commerce from the University of Melbourne. since 2017.
| Tenure | 7 years |
| Address | Australia Square, Sydney, NSW, Australia, 2000 |
| Phone | 61 2 8315 7003 |
| Web | https://www.immutep.com |
Immutep Management Efficiency
The company has return on total asset (ROA) of (0.257) % which means that it has lost $0.257 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4212) %, meaning that it created substantial loss on money invested by shareholders. Immutep's management efficiency ratios could be used to measure how well Immutep manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/01/2024, Return On Tangible Assets is likely to drop to -0.27. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, Immutep's Total Current Liabilities is relatively stable compared to the past year. As of 05/01/2024, Liabilities And Stockholders Equity is likely to grow to about 178 M, while Non Current Liabilities Total is likely to drop slightly above 1.3 M.Similar Executives
| Found 6 records | DIRECTOR Age | ||
| Christopher Paige | AVROBIO | 64 | |
| Someit MD | Zura Bio Limited | 34 | |
| Phillip Donenberg | AVROBIO | 57 | |
| Philip Vickers | AVROBIO | 58 | |
| Annalisa Jenkins | AVROBIO | 51 | |
| Ian Clark | AVROBIO | 57 | |
Management Performance
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.26 |
Immutep Ltd ADR Leadership Team
Elected by the shareholders, the Immutep's board of directors comprises two types of representatives: Immutep inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immutep. The board's role is to monitor Immutep's management team and ensure that shareholders' interests are well served. Immutep's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immutep's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic MD, Chief Director | ||
| Pete Meyers, Non-Executive Director | ||
| Russell Howard, Non-Executive Director | ||
| Indira Naidu, Joint Secretary | ||
| Shengfei Fang, F Sec | ||
| MD MSc, Chief Officer | ||
| Deanne LLB, General COO | ||
| Christian Mueller, Director Affairs | ||
| Frederic Triebel, Chief Scientific Officer & Chief Medical Officer | ||
| MSc BBA, Senior Strategy | ||
| Deanne Miller, COO, General Counsel, Company Secretary | ||
| Grant Chamberlain, Non-Executive Director | ||
| Marc Voigt, CEO, Executive Director | ||
| Matthew Gregorowski, IR Contact Officer |
Immutep Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Immutep a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (10.96) % | ||||
| Current Valuation | 3.07 B | ||||
| Shares Outstanding | 118.88 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.56 % | ||||
| Number Of Shares Shorted | 1.46 M | ||||
| Price To Earning | (152.55) X | ||||
| Price To Book | 3.93 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immutep in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immutep's short interest history, or implied volatility extrapolated from Immutep options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immutep Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Immutep Stock analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Immutep's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immutep. If investors know Immutep will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immutep listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.04 | Quarterly Revenue Growth 0.252 | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Immutep Ltd ADR is measured differently than its book value, which is the value of Immutep that is recorded on the company's balance sheet. Investors also form their own opinion of Immutep's value that differs from its market value or its book value, called intrinsic value, which is Immutep's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immutep's market value can be influenced by many factors that don't directly affect Immutep's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immutep's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immutep is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immutep's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.